Trial Profile

Phase 1b/2 study of BC3402 injection in patients with malignant blood diseases

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BC 3402 (Primary)
Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 Jun 2023 New trial record
13 Jun 2023 According to a WuXi Biologics Media Release, TIM-3 monoclonal antibody BC3402 injection has been approved for phase I and phase lb/ll clinical trials in Zhongmeifen, and it is intended to be used for the treatment of malignant blood diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com